Canaccord Raises AngioDynamics Target Price to $17

Summary

Canaccord Genuity Group has raised AngioDynamics’ (NASDAQ: ANGO) target share price from $15.00 to $17.00, maintaining a ‘buy’ rating. This new target implies a potential upside of 96.53% from the current price. AngioDynamics recently reported a quarterly earnings per share loss of $0.03, exceeding expectations, with revenue growing 13% year-over-year. The stock is currently trading at $8.65, down 10.2%, with a market capitalization of $351.28 million. Institutional investors hold 89.43% of the stock, indicating strong interest in the company.Market Beat

Impact Analysis

This event is classified at the company level, as it specifically pertains to AngioDynamics and its financial outlook. Canaccord’s upward revision of the target price to $17.00 suggests increased confidence in the company’s future performance. The direct (first-order) effect of this announcement may include a positive shift in investor sentiment and potentially increased buying interest, which could help stabilize or increase AngioDynamics’ stock price from its current level of $8.65. The company’s recent financial performance, including a smaller-than-expected earnings loss and revenue growth, also supports this positive view, despite a current downturn in stock price.Market Beat+ 2 However, there remains a risk due to the company’s adjusted annual loss guidance, which could temper long-term investor enthusiasm if not managed effectively.Motley Fool For investors, opportunities may include purchasing the stock at its current depressed price given the expected upside, but they should remain cautious of potential risks related to future earnings adjustments.Market Beat